Cite
HARVARD Citation
Müller, D. et al. (n.d.). Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Leukemia & lymphoma. 57 (5), pp. 1130-1139. [Online].